Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.05
N/A-2.8213,914 shs5 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.49
+0.4%
$2.06
$0.40
$3.10
$201.55M2.052.20 million shs755,783 shs
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
$0.70
-7.7%
$0.53
$0.32
$2.07
$42.44M2.12848,835 shs376,000 shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$0.29
+3.7%
$0.35
$0.26
$2.83
$36.08M0.792.72 million shs1.86 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-83.33%-99.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
0.00%+10.67%+3.75%+446.53%+91.54%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00%0.00%0.00%0.00%0.00%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%-0.34%-21.26%-4.26%-84.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.8358 of 5 stars
3.51.00.04.70.01.71.3
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.6729 of 5 stars
3.51.00.04.11.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33114.19% Upside
Lannett Company, Inc. stock logo
LCI
Lannett
0.00
N/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
0.00
N/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.00
Buy$5.201,693.10% Upside

Current Analyst Ratings Breakdown

Latest CALA, MRSN, LCI, MGTA, and CTMX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/15/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$3.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
5/6/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$4.00 ➝ $3.00
4/14/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M1.45$0.36 per share6.91($0.01) per share-249.00
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/A$1.23 per shareN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$40.50M0.89N/AN/A($0.08) per share-3.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.485.19N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
-$76.46MN/A0.00N/AN/A-70.88%-57.27%N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)

Latest CALA, MRSN, LCI, MGTA, and CTMX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.73
1.73
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
N/A
19.49
19.49
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.83
1.83

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
47.53%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million75.30 millionOptionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
Magenta Therapeutics, Inc. stock logo
MGTA
Magenta Therapeutics
6760.67 million51.46 millionNot Optionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
150124.63 million108.43 millionOptionable

Recent News About These Companies

Mersana Therapeutics Settles Debt with Oxford Finance
Mersana Therapeutics Inc (MRSN) - Investing.com
Q1 2025 Mersana Therapeutics Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.49 +0.01 (+0.40%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.49 0.00 (0.00%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Lannett stock logo

Lannett NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Magenta Therapeutics stock logo

Magenta Therapeutics NASDAQ:MGTA

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

$0.29 +0.01 (+3.68%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$0.30 +0.01 (+1.72%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.